The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.10
Bid: 2.10
Ask: 2.19
Change: -0.075 (-3.45%)
Spread: 0.09 (4.286%)
Open: 2.22
High: 2.22
Low: 2.10
Prev. Close: 2.175
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

20 Apr 2018 08:24

RNS Number : 5795L
Immupharma PLC
20 April 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Immupharma plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Lanstead Capital LP

City and country of registered office (if applicable)

 

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

17/04/2018

6. Date on which issuer notified (DD/MM/YYYY):

19/04/2018

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

0.00%

0.00%

0.00%

139,467,430

Position of previous notification (if

applicable)

5.01%

0.00%

5.01%

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

 

ISIN: GB0033711010

0

0

0.00%

0.00%

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

0

0.00%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

     

 

Place of completion

XLON

Date of completion

17/04/2018

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLDBLBLVZFLBBF
Date   Source Headline
7th Sep 20228:25 amRNSExercise of Options
31st Aug 20227:00 amRNSFDA response for Type C Meeting - update
30th Aug 202211:29 amRNSExercise of Options
24th Aug 20228:11 amRNSExercise of Options
17th Aug 20226:12 pmRNSTR-1 Notification of major holdings
16th Aug 20228:03 amRNSTotal Voting Rights
11th Aug 20227:00 amRNSResult of Broker Option / PDMR Dealings
4th Aug 20227:00 amRNSInvestor Presentation - Investor Meet Company
3rd Aug 20224:40 pmRNSSecond Price Monitoring Extn
3rd Aug 20224:35 pmRNSPrice Monitoring Extension
3rd Aug 20224:33 pmRNSSubscription/Placing to raise £1.1m; Broker Option
26th Jul 20224:41 pmRNSSecond Price Monitoring Extn
26th Jul 20224:35 pmRNSPrice Monitoring Extension
11th Jul 20227:00 amRNSInitiation of Research
7th Jul 20227:00 amRNSConfirmed FDA response date for Type C Meeting
28th Jun 20225:44 pmRNSAdmission of new ordinary shares of £0.01
28th Jun 202211:42 amRNSResult of AGM
27th Jun 20227:00 amRNSUpdate on Lupuzor
20th Jun 20223:22 pmRNSHolding(s) in Company
1st Jun 20227:00 amRNSNotice of AGM & Annual Report & Accounts
25th May 20227:00 amRNSFinals results for y/e 31 December 2021
4th May 20227:00 amRNSUPDATE on LUPUZOR™ PROGRESS to PHASE 3 with AVION
13th Apr 20227:00 amRNSUPDATE on P140 (LUPUZOR™) clinical progress
7th Feb 20227:00 amRNSLUPUZOR UPDATE
10th Jan 20227:00 amRNSTR-1: Notification of major holdings
5th Jan 20229:53 amRNSTR-1: Notification of major holdings
24th Dec 20218:34 amRNSHolding(s) in Company
20th Dec 20217:00 amRNSSubscriptions and Placing to raise £3.55 million
15th Dec 20214:35 pmRNSPrice Monitoring Extension
7th Dec 20214:41 pmRNSSecond Price Monitoring Extn
7th Dec 20214:36 pmRNSPrice Monitoring Extension
29th Nov 20217:00 amRNSCOLLABORATION WITH IMPERIAL COLLEGE LONDON
18th Nov 20217:00 amRNSCorporate Update
8th Nov 20214:41 pmRNSSecond Price Monitoring Extn
8th Nov 20214:36 pmRNSPrice Monitoring Extension
11th Oct 20214:35 pmRNSPrice Monitoring Extension
1st Oct 20217:00 amRNSEuronext Delisting
30th Sep 20217:15 amRNSPROF. SYLVIANE MULLER AWARDED ‘LEGION D’HONNEUR’
29th Sep 20217:30 amRNSInterim Results for the 6months ended 30 June 2021
29th Sep 20217:00 amRNSCorporate Update
22nd Sep 20214:36 pmRNSPrice Monitoring Extension
24th Aug 202111:07 amRNSDirector/PDMR Shareholding
20th Aug 20214:40 pmRNSSecond Price Monitoring Extn
20th Aug 20214:35 pmRNSPrice Monitoring Extension
19th Aug 20214:35 pmRNSPrice Monitoring Extension
17th Aug 20218:50 amRNSNotification of Major Holdings
12th Aug 20217:00 amRNSFDA approves the Lupzuor™ PK study
10th Aug 20214:40 pmRNSSecond Price Monitoring Extn
10th Aug 20214:35 pmRNSPrice Monitoring Extension
30th Jul 20217:00 amRNSBoard Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.